PATROL, a multicenter prospective study published in BJU International on June 9, screens men who carry an inherited pathogenic variant in a prostate cancer risk gene (BRCA2, BRCA1, ATM, CHEK2, HOXB13, and the Lynch syndrome genes) on a different clock than the general population. Carriers start at age 40, and the thresholds that trigger imaging or biopsy sit far below standard practice: biopsy is offered at a PSA above 1.0 ng/mL for men under 50, where many clinics still treat 4.0 as the line. BRCA2 carriers face a prostate cancer risk approaching 60% by age 85, and their disease skews toward the aggressive, higher-grade kind.
20 Jun, 2026